These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30581150)

  • 21. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
    Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
    Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
    Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
    J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
    Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
    Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.
    Spanò V; Pennati M; Parrino B; Carbone A; Montalbano A; Cilibrasi V; Zuco V; Lopergolo A; Cominetti D; Diana P; Cirrincione G; Barraja P; Zaffaroni N
    J Med Chem; 2016 Aug; 59(15):7223-38. PubMed ID: 27428868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma.
    Zhang C; Hao Y; Wu L; Dong X; Jiang N; Cong B; Liu J; Zhang W; Tang D; De Perrot M; Zhao X
    Int J Oncol; 2018 Dec; 53(6):2531-2541. PubMed ID: 30272283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
    Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
    J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
    Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
    Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.
    Teng T; Tsai JH; Puyang X; Seiler M; Peng S; Prajapati S; Aird D; Buonamici S; Caleb B; Chan B; Corson L; Feala J; Fekkes P; Gerard B; Karr C; Korpal M; Liu X; T Lowe J; Mizui Y; Palacino J; Park E; Smith PG; Subramanian V; Wu ZJ; Zou J; Yu L; Chicas A; Warmuth M; Larsen N; Zhu P
    Nat Commun; 2017 May; 8():15522. PubMed ID: 28541300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
    Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
    J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
    Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
    Liang Y; Li C; Liu Y; Tian L; Yang D
    BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
    Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
    Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
    Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression.
    Kawamura N; Nimura K; Saga K; Ishibashi A; Kitamura K; Nagano H; Yoshikawa Y; Ishida K; Nonomura N; Arisawa M; Luo J; Kaneda Y
    Cancer Res; 2019 Oct; 79(20):5204-5217. PubMed ID: 31431456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
    El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
    Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
    Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
    J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
    Deraco M; Cabras A; Baratti D; Kusamura S
    Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells.
    Albert BJ; McPherson PA; O'Brien K; Czaicki NL; Destefino V; Osman S; Li M; Day BW; Grabowski PJ; Moore MJ; Vogt A; Koide K
    Mol Cancer Ther; 2009 Aug; 8(8):2308-18. PubMed ID: 19671752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
    Kim Guisbert KS; Guisbert E
    PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.